ENLV
HealthcareEnlivex Therapeutics Ltd.
$0.78
+$0.03 (+3.44%)
Jan 5, 2026
Price History (1Y)
Analysis
Enlivex Therapeutics Ltd. operates within the healthcare sector and biotechnology industry. The company's market capitalization stands at $185.49M, indicating a sizeable presence in its field. Financially, Enlivex has reported significant losses, with a net income of -$12,701,000 over the trailing twelve months. Its operating margin and profit margin are both 0.0%, suggesting that the company is currently experiencing financial difficulties. The company's cash reserves total $18.20M, while its debt stands at $701,000, resulting in a debt-to-equity ratio of 4.01. The valuation of Enlivex Therapeutics Ltd. can be assessed through various metrics. Its forward P/E ratio is -1.35, indicating that the company's stock price may not accurately reflect its current financial performance. Additionally, the company's return on equity and return on assets are -$57.6% and -36.0%, respectively, suggesting a decline in profitability over time.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Visit website →Key Statistics
- Market Cap
- $185.49M
- P/E Ratio
- N/A
- 52-Week High
- $2.10
- 52-Week Low
- $0.66
- Avg Volume
- 3.97M
- Beta
- 1.52
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- Israel